Secretory leukocyte proteinase inhibitor and elafin are resistant to degradation by MMP-8

Experimental Lung Research

Volumn 28, Issue 2, 2002, Pages 85-97

  Henry, Michael T ^a   Mcmahon, K ^a   Costello, C ^a   FitzGerald, M X ^a   O'Connor, C M ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

1proteinase inhibitor; Elafin; Elastase inhibitors; Matrix metalloproteinase 8; Oxidation; Secretory leukocyte proteinase inhibitor

Indexed keywords

ELAFIN; NEUTROPHIL COLLAGENASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PURIFICATION;

HUMANS; MATRIX METALLOPROTEINASE 8; NEUTROPHILS; OXIDATION-REDUCTION; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SPUTUM; SUBSTRATE SPECIFICITY;

EID: 0036172155     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/019021402753462022     Document Type: Article

References (36)

1. Proteolytic enzymes, their inhibitors and lung diseases
2. Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema
3. α1-Proteinase Inhibitor, elastase activity and lung disease severity in cystic fibrosis
4. The electrophoretic α-1 globulin pattern of serum in α-1 antitrypsin deficiency
5. Guidelines for the approach to the patient with severe alpha-1-antitrypsin deficiency. Official statement of the ATS
6. 1 in patients with severe hereditary alpha 1 antitrypsin deficiency
7. A randomised clinical trial of alpha-1-antitrypsin augmentation therapy
8. Structural evidence for methionine at the reactive site for alpha-1-proteinase inhibitor
9. Myeloperoxidase-catalysed inactivation of α1-protease inhibitor by human neutrophils
10. Oxidative regulation of neutrophil elastase alpha-1-proteinase inhibitor reactions
11. Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase
12. Interstitial collagenase (MMP-1) expresses serpinase activity
13. In vivo collagenase-2 expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis
14. The family of matrix metalloproteinases
15. 1-Antitrypsin by metalloproteinases released from activated neutrophils
16. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha-1-antitrypsin
17. Proteolysis by neutrophils. Relative importance of cell substrate contact and oxidative inactivation of proteinase inhibitors in vitro
18. Localisation of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract
19. Isolation of elafin, an elastase specific inhibitor(ESI) from bronchial secretions: Evidence of sequence homology and immunological cross reactions
20. Regulation of proteolysis at the neutrophil substrate interface by secretory leucoprotease inhibitor
21. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis
22. Secretory leukoprotease inhibitor: Partnering al-proteinase inhibitor to combat pulmonary inflammation
23. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity
24. Elafin/elastase specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung
25. Comparative loss of activity of recombinant secretory leukoprotease inhibitor and α1-protease inhibitor caused by different forms of oxidative stress
26. Characterisation and activation of procollagenase from human polymorphonuclear leucocytes
27. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis
28. Human neutrophil collagenase
29. A rapid procedure for large scale purification of elastase and cathepsin G from human sputum
30. Purification and characterization of human leukocyte elastase
31. 1-antitrypsin treatment for cystic fibrosis
32. Pitfalls in antiprotease therapy of emphysema
33. Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation
34. Anti-neutrophil elastase defence of the normal human respiratory epithelium surface provided by secretory leukoprotease inhibitor
35. Oxidised mucus proteinase inhibitor: A fairly potent neutrophil elastase inhibitor
36. Pulmonary deposition and disappearance of aerosolised secretory leucocyte proteinase inhibitor